The company's attributed the weaker sales to softness in its industrial markets, which have been pressured by soft demand.
Earnings beat the Street however, as its biopharmaceuticals business posted strong performance.
Gross margin was flat at 51.5%, as input costs shrank 0.6%.
Looking forward, the company forecasts earnings of between $3.30 to $3.50 per share on revenue growth in the low to mid-single digits. Analysts are looking for $3.48 a share on 5% revenue growth.